Possible new LNK mutations in myeloproliferative neoplasms

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 866-868

  Ha, Jung Sook ^a   Jeon, Dong Seok ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE 2; LYMPHOCYTE ADAPTOR PROTEIN; PROTEIN SH2; UNCLASSIFIED DRUG;

ADULT; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; EXON; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; LETTER; MALE; MISSENSE MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTHEMIA;

ANIMALS; BONE MARROW NEOPLASMS; CASE-CONTROL STUDIES; CODON, NONSENSE; FEMALE; HUMANS; JANUS KINASE 2; MALE; MICE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY MYELOFIBROSIS; PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84860412097     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22107     Document Type: Letter

References (20)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
4. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
5. Oh ST, Gotlib J. JAK2 V617F and beyond: Role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol 2010; 3: 323-337.
6. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847-1849.
7. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865-1867.
8. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
9. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006; 108: 3472-3476.
10. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004; 200: 569-580.
11. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005; 105: 4604-4612.
12. Rudd CE. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE. 2001; 2001: pe1.
13. Gery S, Gueller S, Chumakova K, et al. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 2007; 110: 3360-3364.
14. Gery S, Cao Q, Gueller S, et al. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 2009; 85: 957-965.
15. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002; 195: 1599-1611.
16. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
17. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24: 1713-1718.
18. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010; 363: 1189-1190.
19. Baran-Marszak F, Magdoud H, Desterke C, et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 2010; 116: 5961-5971.
20. Bersenev A, Wu C, Balcerek J, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010; 120: 2058-2069.